• Ferrostatin-1 (Fer-1): Selective Ferroptosis Inhibitor in Di

  2026-06-02

  Ferrostatin-1 (Fer-1) is a potent, selective ferroptosis inhibitor with demonstrated nanomolar efficacy in preventing lipid peroxidation-driven cell death. Its robust activity underpins diverse experimental workflows in cancer biology, neurodegeneration, and atherosclerosis research. The compound's validated benchmarks and solubility profile make it a cornerstone for studying iron-dependent oxidative damage.

• Phosphatase Inhibitor Cocktail 2: Proteostasis, Aging, and A

  2026-06-01

  Explore how Phosphatase Inhibitor Cocktail 2 enables robust protein phosphorylation preservation in cutting-edge aging and neurodegeneration research. This article uncovers unique mechanistic and protocol-level insights for advanced signaling studies.

• HotStart™ 2X Green qPCR Master Mix: Protocol and Troubleshoo

  2026-06-01

  HotStart™ 2X Green qPCR Master Mix addresses nonspecific amplification and inconsistent quantification in SYBR Green–based real-time PCR workflows. It is best suited for gene expression analysis, RNA-seq validation, and nucleic acid quantification, but should not be substituted for probe-based qPCR or used where dye-based detection is unsuitable.

• Preclinical Characterization of Anlotinib: Selective VEGFR2

  2026-05-31

  This study presents a rigorous preclinical evaluation of anlotinib hydrochloride, a highly selective multi-target tyrosine kinase inhibitor with potent anti-angiogenic effects primarily via VEGFR2 inhibition. The findings highlight anlotinib's superior selectivity, in vitro and in vivo efficacy, and translational relevance for anti-angiogenic cancer research.

• Dual-Action Kinase Inhibitors Facilitate p38α MAPK Dephospho

  2026-05-30

  The referenced study uncovers that certain kinase inhibitors, including those structurally related to Imatinib hydrochloride, not only block kinase catalytic activity but also enhance dephosphorylation of p38α MAP kinase by stabilizing an activation loop conformation accessible to phosphatases. These findings provide a structural basis for dual-action inhibition and suggest new strategies for increasing specificity and potency in kinase inhibitor design for cancer research.

• Liposomal Co-Delivery of Cisplatin and Procainamide Hydrochl

  2026-05-29

  This study introduces a liposomal formulation co-encapsulating cisplatin and procainamide hydrochloride, demonstrating potentiated antiproliferative activity and reduced toxicity compared to cisplatin alone. The findings highlight the dual role of procainamide hydrochloride as both a cardiac sodium channel blocker and a modulator of chemotherapeutic response, suggesting new strategies for combinatorial drug delivery in oncology research.

• ABT-263 (Navitoclax) Workflows: Applied Apoptosis in Cancer

  2026-05-29

  ABT-263 (Navitoclax) is redefining apoptosis research in cancer biology, enabling precise, phase-specific cell death interrogation and translational workflow innovation. This article spotlights advanced experimental strategies, protocol best practices, and troubleshooting guidance for maximizing data quality with this potent Bcl-2 family inhibitor.

• Reliable Protein Labeling: NHS-Biotin (A8002) for Cell Assay

  2026-05-28

  This article delivers a scenario-driven, evidence-based overview of NHS-Biotin (SKU A8002) for researchers tackling challenges in cell viability, proliferation, and cytotoxicity assays. By anchoring each real-world Q&A in lab workflows, it showcases how NHS-Biotin’s chemistry, reproducibility, and vendor reliability translate into robust data and streamlined protocols for biomedical scientists.

• TAK-715 and the Dual-Action Paradigm in p38 MAPK Inhibition

  2026-05-28

  Explore how TAK-715, a potent p38 MAPK inhibitor, is reshaping research with its unique dual-action effects on kinase inhibition and phosphatase-driven deactivation. This in-depth article uniquely deciphers the mechanistic and translational implications for inflammation and cytokine signaling studies.

• Senolytic Effects of L. plantarum DS0037-Derived Nanovesicle

  2026-05-27

  This study reports that exosome-like nanovesicles (ELNs) derived from Lactobacillus plantarum DS0037 exert selective senolytic and senomorphic effects on aging cells. The findings suggest these microbial ELNs modulate gene expression and apoptosis in senescent cells, with potential applications in anti-aging and skin health research.

• Eltanexor (KPT-8602): Precision XPO1 Inhibition in Translati

  2026-05-27

  Eltanexor (KPT-8602) is a next-generation XPO1 inhibitor with refined selectivity, demonstrating potent activity in cancer research. This article uniquely dissects its translational applications, mechanistic nuances, and emerging role as a chemopreventive agent, offering deeper assay guidance than existing resources.

• KPT330 Enhances CRISPR-Cas9 Editing Precision via mRNA Expor

  2026-05-26

  The reference study identifies KPT330, an FDA-approved SINE compound, as an indirect and irreversible modulator of CRISPR-Cas9 specificity by inhibiting Cas9 mRNA nuclear export. This finding demonstrates a novel approach to improving the fidelity of genome and base editing in mammalian cells and expands the available strategies for minimizing off-target effects in CRISPR workflows.

• Nonconventional Agonist-Antagonist Interactions at the GLP-1

  2026-05-26

  This study reveals that glucagon can act as a nonconventional agonist at the GLP-1 receptor, challenging the traditional view of ligand selectivity at GPCRs. High-throughput FRET cAMP assays demonstrate complex interplay between glucagon, GLP-1, and various receptor modulators, with significant implications for metabolic and diabetes research.

• Açaí Extracts: Cytotoxicity and Enzyme Modulation in Human H

  2026-05-25

  This study systematically evaluated various açaí (Euterpe oleracea) extracts for their potential to induce drug-metabolizing enzymes and transporters in human hepatocytes. The findings reveal dose-dependent cytotoxicity for certain extracts but minimal induction of CYP450 enzymes or major transporters, refining our understanding of botanical-drug interaction risks and supporting safer supplement use in clinical contexts.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-05-25

  This study provides mechanistic insights into how cannabidiol (CBD) alleviates both sensory and affective components of orofacial inflammatory pain in mouse models. By dissecting peripheral and central endocannabinoid signaling, the research underscores CBD’s translational potential for comprehensive pain and comorbidity management.

8371 records 14/559 page Previous Next First page 上5页 1112131415 下5页 Last page